WO2002012477A3 - Enhanced replication of hcv rna - Google Patents

Enhanced replication of hcv rna Download PDF

Info

Publication number
WO2002012477A3
WO2002012477A3 PCT/US2001/024276 US0124276W WO0212477A3 WO 2002012477 A3 WO2002012477 A3 WO 2002012477A3 US 0124276 W US0124276 W US 0124276W WO 0212477 A3 WO0212477 A3 WO 0212477A3
Authority
WO
WIPO (PCT)
Prior art keywords
provides methods
hcv rna
enhanced replication
cells
rna replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/024276
Other languages
French (fr)
Other versions
WO2002012477A2 (en
Inventor
Hui-Hua Lu
Mark Selby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to DE60117561T priority Critical patent/DE60117561T2/en
Priority to EP01956106A priority patent/EP1320583B1/en
Priority to CA2416633A priority patent/CA2416633C/en
Priority to AU2001278139A priority patent/AU2001278139A1/en
Publication of WO2002012477A2 publication Critical patent/WO2002012477A2/en
Anticipated expiration legal-status Critical
Publication of WO2002012477A3 publication Critical patent/WO2002012477A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

This invention provides methods for generating cells that stably replicate sub-genomic virus replicons. This invention also provides methods of generating cells that have disabled PKR activity and that stably replicate HCV subgenomic replicons. The invention also provides methods of using the cells of the invention to screen for compounds that modulate viral RNA replication, including HCV RNA replication.
PCT/US2001/024276 2000-08-04 2001-08-03 Enhanced replication of hcv rna Ceased WO2002012477A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE60117561T DE60117561T2 (en) 2000-08-04 2001-08-03 IMPROVED REPLICATION OF HCV RNA
EP01956106A EP1320583B1 (en) 2000-08-04 2001-08-03 Enhanced replication of hcv rna
CA2416633A CA2416633C (en) 2000-08-04 2001-08-03 Enhanced replication of hcv rna
AU2001278139A AU2001278139A1 (en) 2000-08-04 2001-08-03 Enhanced replication of hcv rna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22324400P 2000-08-04 2000-08-04
US60/223,244 2000-08-04

Publications (2)

Publication Number Publication Date
WO2002012477A2 WO2002012477A2 (en) 2002-02-14
WO2002012477A3 true WO2002012477A3 (en) 2003-04-10

Family

ID=22835673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024276 Ceased WO2002012477A2 (en) 2000-08-04 2001-08-03 Enhanced replication of hcv rna

Country Status (7)

Country Link
US (2) US6660471B2 (en)
EP (1) EP1320583B1 (en)
AT (1) ATE318893T1 (en)
AU (1) AU2001278139A1 (en)
CA (1) CA2416633C (en)
DE (1) DE60117561T2 (en)
WO (1) WO2002012477A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050822B1 (en) * 2001-01-23 2013-07-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis C virus replicons and replicon enhanced cells
EP1490389A4 (en) * 2002-04-03 2006-08-09 Smithkline Beecham Corp Hepatitis c virus sub-genomic replicons
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
SG189212A1 (en) 2010-09-03 2013-05-31 Stem Centrx Inc Identification and enrichment of cell subpopulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
WO1999023203A1 (en) * 1997-11-03 1999-05-14 New York University Immortalized, homozygous stat1-deficient mammalian cell lines and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
WO1999023203A1 (en) * 1997-11-03 1999-05-14 New York University Immortalized, homozygous stat1-deficient mammalian cell lines and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOHMANN V ET AL: "REPLICATION OF SUBGENOMIC HEPATITIS C VIRUS RNAS IN A HEPATOMA CELLLINE", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 285, 2 July 1999 (1999-07-02), pages 110 - 113, XP000960693, ISSN: 0036-8075 *
RIVAS-ESTILLA ANA MARIA ET AL: "PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone.", JOURNAL OF VIROLOGY, vol. 76, no. 21, November 2002 (2002-11-01), November, 2002, pages 10637 - 10653, XP001109362, ISSN: 0022-538X *

Also Published As

Publication number Publication date
EP1320583A2 (en) 2003-06-25
US20040076612A1 (en) 2004-04-22
AU2001278139A1 (en) 2002-02-18
WO2002012477A2 (en) 2002-02-14
US7183107B2 (en) 2007-02-27
ATE318893T1 (en) 2006-03-15
DE60117561T2 (en) 2007-01-11
CA2416633A1 (en) 2002-02-14
DE60117561D1 (en) 2006-04-27
US20020142455A1 (en) 2002-10-03
EP1320583B1 (en) 2006-03-01
US6660471B2 (en) 2003-12-09
CA2416633C (en) 2013-04-30

Similar Documents

Publication Publication Date Title
ATE472335T1 (en) CHIMERE ALPHAVIRUS REPLICON PARTICLES
MA29924B1 (en) COMPOUNDS AND METHODS FOR INHIBITING VIRAL REPLICATION OF HEPATITIS C
DK1618888T3 (en) Preparation of human papillomavirus capsid protein and virus-like particles
FR20C1016I1 (en)
UA85536C2 (en) Viral antigens
ATE355380T1 (en) METHOD FOR SELECTIVE INACTIVATION OF VIRAL REPLICATION
NO20004104D0 (en) Preparations comprising viruses and methods for concentrating virus preparations
NO20090865L (en) Vaccine
SG155053A1 (en) Method of obtaining viable human liver cells, including hepatic stem/progenitor cells
IL147969A0 (en) Peptides that block viral infectivity and methods of use thereof
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO2005087931A8 (en) Modified oncolytic viruses
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
TW200508247A (en) Sars
EP1274305A4 (en) AIDS VIRUSES AND ANCESTRAL VACCINES
AU2001278139A1 (en) Enhanced replication of hcv rna
WO2001097824A3 (en) Use of phyllanthus constituents for treating or preventing infections caused by flaviviridae
MXPA02012593A (en) Bvdv virus-like particles.
AUPQ810900A0 (en) Viral variants and methods of using same
EP1141255A4 (en) Modified forms of hepatitis c virus ns3 protease
DE69738512D1 (en) EPSTEIN-BARR VIRUS TYPE B CTL EPITOPES
WO2004048403A3 (en) Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element
WO2002087600A8 (en) Use of phyllanthus constituents for treating or preventing infections caused by hepatit
TR200201954T2 (en) Medicinal substances for viral diseases.
WO2003085084A3 (en) Hepatitis c virus sub-genomic replicons

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2416633

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001956106

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001956106

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001956106

Country of ref document: EP